GSK playing the lung game with $10.6B Nuvalent-buy strategy

Ahead of an approval bid with its own candidate in non-small-cell lung cancer (NSCLC), GSK plc is planting a stake in the space by way of the $10.6 billion buyout of Nuvalent Inc. for $124 per share, a 40% premium to Nuvalent’s last closing price and a 26% premium to the 30-calendar day amount. Net of cash acquired, GSK’s investment will total about $9.4 billion.